Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121713 | 0.82 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1RAB9AKMT2AMEN1 | |
| SCHEMBL4125720 | 0.82 | DPP7 (0.41) | SMN1; SMN2ALDH1A1CYP3A4CYP2C19RAB9A | |
| SCHEMBL4128646 | 0.80 | DPP7 (0.43) | SMN1; SMN2ALDH1A1CYP3A4CYP2C19RAB9A | |
| SCHEMBL16358958 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2USP2ALDH1A1PKMCYP3A4 | |
| SCHEMBL4108525 | 0.78 | CYP1A2 (0.45) | TP53 | |
| SCHEMBL8395805 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1PKMCYP3A4CYP2C19 | |
| SCHEMBL4121638 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2USP2ALDH1A1PKMCYP3A4 | |
| SCHEMBL4121643 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2USP2ALDH1A1PKMCYP3A4 | |
| SCHEMBL824919 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1PKMCYP3A4CYP2C19 | |
| SCHEMBL5486914 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1PKMCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | SMN1; SMN2 3382/4885USP2 3764/4885ALDH1A1 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.